Pancreatic Ductal Adenocarcinoma
Conditions
Interventions
Experimental group:Ninituzumab + Gemcitabine plus albumin-bound purpurinol+Radical resection
Sponsors
West China Hospital , Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: . Age range: 18 to 75 years old. 2. Histopathologically or cytologically confirmed pancreatic ductal adenocarcinoma. 3. Initial imaging evaluation according to the NCCN Guidelines 2022 for locally advanced, unresectable pancreatic cancer. 4. Eastern Cooperative Oncology Group (ECOG) performance status score =2. 5. Adequate liver, cardiac, renal, and bone marrow function (absolute neutrophil count >1500/mm3, platelet count >150,000/µl, creatinine clearance >60 ml/min). 6. Obtained informed consent from both the patient and their family.
Exclusion criteria
Exclusion criteria: 1. Non-locally progressive tumors with definite metastasis (M1) are present. 2. Individuals with serious or uncontrolled medical conditions and those who are infected. 3. Patients requiring management of seizures, such as steroid or antiepileptic therapy. 4. Those unable to tolerate neoadjuvant therapy and nituzumab. 5. Any unstable conditions or factors that may compromise patient safety and compliance. 6. Participants who have previously undergone chemotherapy, radiotherapy, or other antitumor therapies before the trial. 7. Pregnant women, those at risk of becoming pregnant, and breastfeeding individuals.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The radical resection rate (R0);Conversion Rate;Objective response rate (ORR);Tumor regression Scale (TRG); | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival (PFS);Disease-free survival (DFS);Overall survival (OS);Complication rate; | — |
Countries
China
Contacts
Public ContactYi Zhang
Department of Pancreatic Surgery, West China Hospital, Sichuan University
Outcome results
None listed